Document:

EX-4.1

LOAN AND SECURITY AGREEMENT

THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 16, 2007 and is entered into by
and between MEMORY PHARMACEUTICALS CORP., a Delaware corporation (the “Borrower”), and HERCULES
TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”).

RECITALS

A. Borrower has requested Lender to make available to Borrower a loan in an aggregate
principal amount of up to Ten Million Dollars ($10,000,000); and

B. Lender is willing to make the loan on the terms and conditions set forth in this Agreement.

AGREEMENT

	 	 	 
	NOW, THEREFORE, Borrower and Lender agree as follows:

	 
	 	 
	ARTICLE 1

	 	DEFINITIONS AND RULES OF CONSTRUCTION

1.1 Capitalized terms used herein and not otherwise defined, have the meanings given to them
in the UCC. The following capitalized terms shall have the following meanings:

“Account Control Agreement” means any agreement entered into by and among the Lender, Borrower
and a third party Bank or other institution (including a Securities Intermediary) in which Borrower
maintains a Deposit Account or Investment Property and which is intended to perfect Lender’s
security interest in any of the Collateral.

“Advance” means any funds advanced under this Agreement.

“Advance Date” means the funding date of any Advance.

“Advance Request” means a request for an Advance submitted by Borrower to Lender in
substantially the form of Exhibit A.

“Affiliate” means with respect to any Person (as defined below), any other Person controlling,
controlled by or under direct or indirect common control with such Person (for the purposes of this
definition “control,” when used with respect to any specified Person, shall mean the power to
direct the management and policies of such person, directly or indirectly, whether through
ownership of voting securities, by contract or otherwise; and the terms “controlling” and
“controlled” shall have meanings correlative to the foregoing).

“Agreement” means this Loan and Security Agreement, as the same may be amended, modified,
supplemented or restated from time to time in accordance with the terms hereof.

“Borrower Products” means all products, technical data or technology currently being designed,
manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the
future including any products under development, collectively, together with all products,
technical data or technology that have been sold, licensed or distributed by Borrower since its
incorporation.

“Business Day” means any day when banks in California, New Jersey and New York are open for
conducting general commercial business.

“Cash” means all cash and cash equivalents.

“Cash Burn” means an amount determined by dividing (i) “A” minus “B,” by (ii) 12, where “A”
equals Borrower’s Cash balance on the last day of the month for which the most recent financial
statements of the Borrower have been delivered under Section 7.1, and “B” equals the Borrower’s
Cash balance on the first day of the 12- month period ending on the date referred to in “A;”
provided, that, in determining the amount of Cash, there shall be excluded from that calculation
any Cash received during such 12-month period from any borrowing and any sale or issuance of
Borrower’s securities, and any Cash paid for capital equipment.

“Closing Date” means the date of this Agreement.

“Collaboration” means any collaboration, license, joint venture, strategic alliance, or
similar agreement or arrangement entered into by Borrower relating to the identification,
acquisition through licensing or otherwise, licensing, development, manufacture, marketing, sale or
other commercialization activities with respect to any Intellectual Property of the Borrower or of
any other Person or with respect to any Borrower Products, in all cases undertaken in the ordinary
course of business , and on terms that are not commercially unreasonable, for a company in the
biotechnology or biopharmaceutical industry.

“Collateral” means the property described in Section 3.

“Commitment Fee” means the commitment fee in the amount of $38,000 previously paid by the
Borrower to Lender.

“Contingent Obligation” means, as applied to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend,
letter of credit or other obligation of another, including any such obligation directly or
indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in
respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with
respect to undrawn letters of credit, corporate credit cards or merchant services issued for the
account of that Person; and (iii) all obligations arising under any interest rate, currency or
commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other
agreement or arrangement designated to protect a Person against fluctuation in interest rates,
currency exchange rates or commodity prices; provided, however, that the term “Contingent
Obligation” shall not include endorsements for collection or deposit in the ordinary course of
business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the
stated or determined amount of the primary obligation in respect of which such Contingent
Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability
in respect thereof as determined by such Person in good faith; provided, however, that such
amount shall not in any event exceed the maximum amount of the obligations under the guarantee or
other support arrangement.

“Copyrights” means all copyrights, whether registered or unregistered, and all applications
therefor, held pursuant to the laws of the United States, any State thereof, or of any other
country.

“Copyright License” means any written agreement granting any right to use any Copyright or
Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds
or hereafter acquires any interest.

“Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and
includes any checking account, savings account, or certificate of deposit.

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the
regulations thereunder.

“Event of Default” has the meaning given to it in Section 9.

“Excluded Assets” means (i) any asset to the extent that (a) such asset is not assignable or
capable of being encumbered as a matter of law or under the terms of the license, lease or other
agreement applicable thereto (but solely to the extent that any such restriction shall be
enforceable under applicable law, including Section 9-408 of the Uniform Commercial Code (or the
corresponding provision) as in effect in any relevant jurisdiction), without the consent of the
licensor or lessor thereof or other applicable party thereto and (b) such consent has not been
obtained; (ii) any Intellectual Property that is owned or licensed by the Borrower and any license
agreements related to such Intellectual Property and (iii) any Equipment subject to a Lien
described in clause (vi) of the definition of Permitted Liens to the extent the agreement or lease
pursuant to which Borrower has an interest in such Equipment prohibits the granting of a security
interest to Lender, provided that upon the termination of such prohibition the Equipment shall
cease to be an Excluded Asset; provided, however, that the proceeds arising from any
disposition of Excluded Assets shall not constitute Excluded Assets.

“Facility Charge” means one-half of one percent (.50%) of the Maximum Loan Amount.

“Financial Statements” has the meaning given to it in Section 7.1.

“GAAP” means generally accepted accounting principles in the United States of America, as in
effect from time to time.

“Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed
money or the deferred purchase price of property or services, including reimbursement and other
obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by
notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all
Contingent Obligations.

“Intellectual Property” means all Copyrights; Trademarks; Patents; Licenses; inventions,
invention records and associated records, laboratory notebooks, discoveries and ideas (whether
patentable or not); biological materials, trade secrets, proprietary information, know how,
confidential information, technology and technical data, and all documentation relating to any of
the foregoing and rights to limit the use of disclosure thereof by any person; writings and other
works, whether copyrightable or not; databases and data collections and all rights therein;
computer software including all source code, object code, firmware, development tools, files,
records and data, all media on which any of the foregoing is recorded; and Web addresses, sites and
domain names; applications for any of the foregoing and reissues, extensions, or renewals of any of
the foregoing; all goodwill associated with any of the foregoing, together with all rights to sue
for past, present and future infringement of any of the foregoing.

“Interest Rate” means with respect to any Advance, the prime rate as reported in The Wall
Street Journal on the date the Borrower submits an Advance Request with respect to such Advance,
plus 3.20%.

“Investment” means any beneficial ownership (including stock, partnership or limited liability
company interests) of or in any Person, or any loan, advance or capital contribution to any Person,
but excluding any prepaid expenses that are reflected from time to time on the Borrower’s balance
sheet.

“Joinder Agreements” means for any Subsidiary, a completed and executed Joinder Agreement in
substantially the form attached hereto as Exhibit G.

“Lender” has the meaning given to it in the preamble to this Agreement.

“License” means any Copyright License, Patent License, Trademark License or other license of
rights or interests.

“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security,
security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or
arising by operation of law or otherwise, against any property, any conditional sale or other title
retention agreement and any lease in the nature of a security interest, but excluding any license
or other right granted by the Borrower in connection with a Collaboration other than a security
interest under the UCC.

“Loan” means the Advance or Advances made under this Agreement.

“Loan Documents” means this Agreement, the Notes, Account Control Agreements, Joinder
Agreements, all UCC Financing Statements, and any other documents executed in connection with the
Secured Obligations or the transactions contemplated hereby, as the same may from time to time be
amended, modified, supplemented or restated.

“Material Adverse Effect” means a material adverse effect upon: (i) the business, operations,
properties, assets, condition (financial or otherwise) or prospects of Borrower; or (ii) the
ability of Borrower to perform the Secured Obligations in accordance with the terms of the Loan
Documents; provided, however, that Borrower’s failure to achieve a Milestone in and of
itself shall not constitute a Material Adverse Effect.

“Maturity Date” means February 16, 2011.

“Maximum Loan Amount” means $10,000,000.

“Maximum Rate” shall have the meaning assigned to such term in Section 2.5.

“Milestone” shall have the meaning set forth on Schedule 1A.

“Note” means a Promissory Note in substantially the form of Exhibit B.

“Patent License” means any written agreement granting any right with respect to any invention
on which a Patent is in existence or a Patent application is pending, in which agreement Borrower
now holds or hereafter acquires any interest.

“Patents” means all letters patent, or rights corresponding thereto, in the United States or
in any other country, all registrations and recordings thereof, and all applications for letters
patent or rights corresponding thereto, in the United States or any other country, and all
reexaminations, reissues, divisions, renewals, extensions, provisionals, continuations and
continuations-in-part of any of the foregoing.

“Payment Date” shall have the meaning assigned to such term in Section 2.4.

“Permitted Indebtedness” means: (a) Indebtedness of Borrower in favor of Lender arising under
this Agreement or any other Loan Document; (b) Indebtedness existing on the Closing Date and
disclosed in Schedule 1B; (c) Indebtedness of up to $2,600,000 in principal amount outstanding at
any time secured by Liens described in clause (vi) of the defined term “Permitted Liens,”; (d)
Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness
incurred in the ordinary course of business with corporate credit cards; (e) Indebtedness that also
constitutes a Permitted Investment; and (f) extensions, refinancings and renewals of any items of
Permitted Indebtedness, provided that the principal amount is not increased or the terms modified
to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.

“Permitted Investment” means: (a) Investments existing on the Closing Date disclosed in
Schedule 1C; (b) (i) marketable direct obligations issued or unconditionally guaranteed by the
United States of America or any agency or any State thereof maturing within one year from the date
of acquisition thereof, (ii) commercial paper maturing no more than one year from the date of
creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s
Corporation or Moody’s Investors Service, (iii) certificates of deposit issued by any bank with
assets of at least $500,000,000 maturing no more than one year from the date of investment therein,
and (iv) money market accounts; (c) Repurchases of stock from former employees, directors, or
consultants of Borrower under the terms of applicable repurchase agreements at the original
issuance price of such securities in an aggregate amount not to exceed $250,000 in any fiscal year,
provided that no Event of Default has occurred, is continuing or would exist after giving effect to
the repurchases; (d) Investments made or accepted in connection with Permitted Transfers; (e)
Investments (including debt obligations) received in connection with the bankruptcy or
reorganization of customers or suppliers and in settlement of delinquent obligations of, and other
disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (f)
Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to
customers and suppliers who are not Affiliates, in the ordinary course of business, provided that
this subparagraph (f) shall not apply to Investments of Borrower in any Subsidiary; (g) additional
Investments that do not exceed $250,000 in the aggregate; (h) Investments made in connection with
any Collaboration; and (i) the acquisition by the Borrower of any beneficial ownership (including
stock, partnership or limited liability company interests) of or in any Person operating in the
biotechnology or biopharmaceutical industry, provided that (i) such acquisition is approved by the
board of directors of the Borrower, (ii) the Borrower does not create, incur, assume, guarantee or
be or become liable with respect to any Indebtedness other than Permitted Indebtedness or any Liens
other than Permitted Liens in connection with such acquisition, and (iii) after giving effect to
such acquisition, Borrower has unrestricted cash equal to the greater of $15,000,000 or six times
the applicable Cash Burn.

“Permitted Liens” means any and all of the following: (i) Liens created under this Agreement
or under the other Loan Documents and Liens existing on the Closing Date disclosed in Schedule 1D;
(ii) Liens for taxes, fees, assessments or other governmental charges or levies, either not
delinquent or being contested in good faith by appropriate proceedings; provided, that
Borrower maintains adequate reserves therefor in accordance with GAAP; (iii) Liens securing claims
or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like
Persons arising in the ordinary course of Borrower’s business; provided, that the payment
thereof is not overdue by more than 30 days; (iv) Liens arising from judgments, decrees or
attachments in circumstances which do not constitute an Event of Default hereunder; (v) the
following deposits, to the extent made in the ordinary course of business: deposits under worker’s
compensation, unemployment insurance, social security and other similar laws, or to secure the
performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to
secure indemnity, performance or other similar bonds for the performance of bids, tenders or
contracts (other than for the repayment of borrowed money) or to secure statutory obligations
(other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to
secure indemnity, performance or other similar bonds; (vi) purchase money Liens and Liens in
connection with capital leases on Equipment securing Indebtedness up to the dollar amount specified
in clause (c) of “Permitted Indebtedness”; (vii) Liens consisting of zoning restrictions,
easements, licenses, restrictions on the use of any property (real, personal or mixed) or minor
imperfections in title thereto that, in the aggregate are not material in amount, and which do not,
in the aggregate detract from the value of such property; (viii) Liens consisting of bankers’ liens
and rights of setoff, in each case, arising by operation of law; (ix) Liens incurred in connection
with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type
described in clauses (i) through (ix) above; provided, that any extension, renewal or
replacement Lien shall be limited to the property encumbered by the existing Lien and the principal
amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any
payment thereon) does not increase.

“Permitted Transfers” means (i) sales of Inventory in the ordinary course of business, (ii)
dispositions of worn-out or obsolete Equipment or Equipment that is no longer used or useful, or
(iii) licenses or other transfers of Intellectual Property or any other asset or property made in
connection with any Collaboration.

“Person” means any individual, sole proprietorship, partnership, joint venture, trust,
unincorporated organization, association, corporation, limited liability company, institution,
other entity or government.

“Preferred Stock” means at any given time any equity security issued by Borrower that has any
rights, preferences or privileges senior to Borrower’s common stock.

“Prepayment Event” means (i) any sale of all, or substantially all, of the assets of Borrower,
or (ii) any reorganization, recapitalization, consolidation or merger (or similar transaction or
series of related transactions) of Borrower or sale or exchange of outstanding shares (or similar
transaction or series of related transactions) of Borrower, in each case in which the holders of
Borrower’s outstanding shares immediately before consummation of such transaction or series of
related transactions do not, immediately after consummation of such transaction or series of
related transactions, retain shares representing at least more than fifty percent (50%) of the
voting power of the surviving entity of such transaction or series of related transactions (or the
parent of such surviving entity if such surviving entity is wholly owned by such parent), in each
case without regard to whether Borrower is the surviving entity.

“Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper,
Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit
Rights, and (ii) all customer lists, software, and business records related thereto.

“SEC Documents” means all reports, schedules, forms, statements and other documents filed
prior to the date hereof by the Borrower with the Securities and Exchange Commission, pursuant to
the reporting requirements of the Securities Exchange Act of 1934, as amended, and all exhibits
included therein and financial statements and schedules thereto and documents (other than exhibits)
incorporated by reference therein.

“Secured Obligations” means Borrower’s obligation to repay to Lender the Loan (whether or not
evidenced by any Note), together with all interest, fees, costs, professional fees and expenses, or
other liabilities or obligations for monetary amounts owed by Borrower to Lender arising under this
Agreement, the Notes, or any other Loan Document, including the indemnity and insurance obligations
in Section 6 and including such amounts as may accrue or be incurred before or after default or
workout or the commencement of any liquidation, dissolution, bankruptcy, receivership or
reorganization by or against Borrower, whether due or to become due, matured or unmatured,
liquidated or unliquidated, contingent or non-contingent, and all covenants and duties of any kind
or nature, present or future, in each case, arising under this Agreement, the Notes, or any of the
other Loan Documents, as the same may from time to time be amended, modified, supplemented or
restated, whether or not such obligations are partially or fully secured by the value of
Collateral.

“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint
venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting
securities, including each entity listed on Schedule 1 hereto.

“Trademark License” means any written agreement granting any right to use any Trademark or
Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds
or hereafter acquires any interest.

“Trademarks” means all trademarks, trade names, service marks brand names, certification
marks, trade dress and other indications of origin, the goodwill associated with the foregoing
(registered, common law or otherwise) and any applications in connection therewith, including
registrations, recordings and applications in the United States Patent and Trademark Office or in
any similar office or agency of the United States, any State thereof or any other country or any
political subdivision thereof, including any extensions, modifications or renewals of any of the
foregoing.

“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the
State of California; provided, that in the event that, by reason of mandatory provisions of
law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s
Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to
time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall
mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely
for purposes of the provisions thereof relating to such attachment, perfection, priority or
remedies and for purposes of definitions related to such provisions. Unless otherwise defined
herein or in the other Loan Documents, terms that are defined in the UCC and used herein or in the
other Loan Documents shall, unless the context indicates otherwise, have the meanings given to them
in the UCC.

“Warrant” means the warrant entered into in connection with the Loan, substantially in the
form of Exhibit G.

1.2 Unless otherwise specified, all references in this Agreement or any Annex or Schedule
hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the
corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless
otherwise specifically provided herein, any accounting term used in this Agreement or the other
Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all
financial computations hereunder shall be computed in accordance with GAAP, consistently applied.

ARTICLE 2 THE LOAN

2.1 Advances. Subject to the terms and conditions of this Agreement, within two days
after the Closing Date, Lender shall fund an initial Advance in the principal amount of $6,000,000
(“Tranche A”). Beginning September 15, 2007, and continuing through December 31, 2007, Borrower
may request additional Advances in an aggregate amount of up to $4,000,000 (“Tranche B”).

2.2 Advance Request. To obtain an Advance, Borrower shall complete, sign and deliver
an Advance Request and Note to Lender. Lender shall fund the Advance no later than 12:00 p.m.
(California time) on the next Business Day following the date the Advance Request is delivered by
the Borrower in the manner requested by the Advance Request, provided that each of the conditions
precedent to such Advance is satisfied as of the date of the Advance Request.

2.3 Interest. The principal balance of each Advance shall bear interest thereon from
the Advance Date at the Interest Rate based on a year consisting of 360 days, with interest
computed daily based on the actual number of days elapsed (including the first day, but excluding
the last day). The Interest Rate for each Advance will be fixed on the date of that Advance, and
will apply to that Advance for so long as it is outstanding, including during the period of
amortization.

2.4 Payment. Borrower will pay accrued interest in arrears on each Advance on the
last Business Day of each month, beginning with the first month after the Advance Date. Borrower
shall repay the aggregate principal amount of the Loans that are outstanding on May 16, 2008 in
thirty (30) equal monthly installments of principal and interest beginning on the last Business Day
of June, 2008, provided however, that if Borrower completes any two Milestones on or prior to the
first anniversary of the Closing Date, then Borrower shall repay the aggregate principal amount of
the Loans that is outstanding on May 16, 2008 in 33 equal monthly installments of principal and
interest beginning on the last Business Day of June 2008 and continuing on the last Business Day of
each month thereafter. Each date on which a payment is due under this Section 2.4 is referred to
as a “Payment Date.” The entire principal amount of the Loans and all accrued but unpaid interest
hereunder remains due and payable on February 16, 2011. Borrower shall make all payments under
this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or
defense.

2.5 Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or
any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest
at a rate that is greater than the maximum rate permissible by law that a court of competent
jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be
deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum
Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually
paid to Lender an amount of interest in excess of the amount that would have been payable if all of
the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess
interest actually paid by Borrower shall be applied as follows: first, to the payment of principal
outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s accrued
interest, costs, expenses, professional fees and any other Secured Obligations; and third, after
all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.

2.6 Default Interest. In the event any payment required under Section 2.4 (but not
under Section 2.7) is not paid on the scheduled Payment Date, a one-time penalty in an amount equal
to five percent (5%) of the past due amount shall be payable by Borrower on demand. In addition,
upon the occurrence and during the continuation of an Event of Default hereunder, all Secured
Obligations to the extent then due and owing (including principal, interest, and professional fees)
shall during such period bear interest at a rate per annum equal to the rate set forth in Section
2.2 plus five percent (5%) per annum.

2.7 Prepayment and Termination of Commitments. Upon at least 5 business days prior
written notice, Borrower may prepay all or any part of the Advances by paying the outstanding
principal amount and all accrued but unpaid interest and fees, plus a prepayment premium equal to
(i) 2.5% of the principal prepaid if paid on or before June 16, 2008, and (ii) 1.5% of the
principal prepaid if paid anytime after June 16, 2008 but before the Maturity Date. Once repaid,
Borrower may not reborrow any Advances. Each notice of a prepayment pursuant to this Section 2.7
shall be irrevocable, provided that a notice may be conditioned upon the effectiveness or closing
of other credit facilities or debt or equity financings, in which case, such notice may be revoked
by the Borrower by notice to the Lender if such condition is not satisfied. All Secured
Obligations shall at Lender’s option become immediately due and payable upon the occurrence of a
Prepayment Event. The Borrower shall have the right at any time to terminate the Lender’s
obligation to fund the Advances by giving the Lender written notice of such election to terminate.
Such termination shall be effective upon receipt of such notice by the Lender.

2.8 End of Term Charge. On the earliest to occur of (i) the Maturity Date, (ii) the
date that Borrower prepays the outstanding Advances, or (iii) the Secured Obligations become due
and payable, Borrower shall pay Lender a charge of three percent (3.0%) of all Advances drawn by
Borrower hereunder.

ARTICLE 3 SECURITY INTEREST

3.1 As security for the prompt, complete and indefeasible payment when due (whether on the
Payment Dates or otherwise) of all the Secured Obligations, Borrower grants to Lender a first
priority security interest (subject to Permitted Liens) in all of Borrower’s personal property now
owned or hereafter acquired, including the following (collectively, the “Collateral”): (a)
Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles; (e) Accounts; (f) Inventory; (g)
Investment Property; (h) Deposit Accounts; (i) Cash; (j) Goods and other tangible and intangible
personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or
to, or acquired by, Borrower and wherever located; and (k) to the extent not otherwise included,
all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for,
and rents, profits and products of each of the foregoing, provided that Collateral does not include
any Excluded Assets.

ARTICLE 4 CONDITIONS PRECEDENT TO LOAN

The obligations of Lender to make the Loan hereunder are subject to the satisfaction by
Borrower of the following conditions:

4.1 Closing Date. On or prior to the Closing Date, Borrower shall have delivered to
Lender the following:

(a) executed originals of the Loan Documents, a legal opinion of Borrower’s counsel, and all
other documents and instruments reasonably required by Lender to effectuate the transactions
contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in
all cases in form and substance reasonably acceptable to Lender;

(b) certified copy of resolutions of Borrower’s board of directors evidencing approval of (i)
the Loans and other transactions evidenced by the Loan Documents; and (ii) the Warrant and
transactions evidenced thereby;

(c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through
the Closing Date, of Borrower;

(d) a certificate of good standing for Borrower from the Secretary of State of the State of
Delaware and the State of New Jersey;

(e) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable
pursuant to Section 11.11 less the Commitment Fee, which amounts may be deducted from the initial
Advance;

(f) the Warrant; and

(g) such other documents as Lender may reasonably request.

4.2 All Advances. On each Advance Date, as a condition to such Advance:

(a) Lender shall have received an Advance Request for the relevant Advance as required by
Section 2.2, and a Note, each duly executed by Borrower’s Chief Executive Officer or Vice
President/Controller.

(b) The representations and warranties set forth in Section 5 of the Agreement shall be true
and correct in all material respects on and as of the Advance Date with the same effect as though
made on and as of such date, except to the extent such representations and warranties expressly
relate to an earlier date.

(c) Borrower shall be in compliance in all material respects with all the terms and provisions
set forth herein and in each other Loan Document on its part to be observed or performed, and at
the time of and immediately after such Advance no Event of Default shall have occurred and be
continuing.

(d) Each Advance Request shall be deemed to constitute a representation and warranty by
Borrower on the relevant date of the Advance Request as to the matters specified in paragraphs (b)
and (c) of this Section and as to the matters set forth in the Advance Request.

(e) No fact or condition shall exist that constitutes or, with the passage of time, the giving
of notice, or both, would constitute, an Event of Default, and no Material Adverse Effect shall
have occurred and be continuing.

ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BORROWER

Borrower represents, warrants and agrees that:

5.1 Corporate Status. Borrower is a corporation duly organized, legally existing and
in good standing under the laws of the State of Delaware, and is duly qualified as a foreign
corporation in all jurisdictions in which the nature of its business or location of its properties
require such qualifications and where the failure to be qualified could reasonably be expected to
have a Material Adverse Effect. Borrower’s present name, former names (if any), locations, state
of incorporation, tax identification number, organizational identification number are correctly set
forth in Exhibit C.

5.2 Collateral. Borrower owns all right, title and interest in and to the Collateral,
free of all Liens, except for Permitted Liens. Borrower has the full power and authority to grant
and convey to Lender a Lien in the Collateral as security for the Secured Obligations, free of all
other Liens other than Permitted Liens.

5.3 Consents. Borrower’s execution, delivery and performance of the Notes, this
Agreement and all other Loan Documents, and Borrower’s execution of the Warrant, (i) have been duly
authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or
imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by
this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s
Certificate of Incorporation, bylaws, or any, law, regulation, order, injunction, judgment, decree
or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate
any material contract or agreement or require the consent or approval of any other Person. The
individual or individuals executing the Loan Documents and the Warrant are duly authorized to do
so.

5.4 Material Adverse Effect. No event that has had or could reasonably be expected to
have a Material Adverse Effect has occurred and is continuing.

5.5 Actions Before Governmental Authorities. Except as described on Schedule
5.5, there are no actions, suits or proceedings at law or in equity or by or before any
governmental authority now pending or, to the knowledge of Borrower, threatened against or
affecting Borrower or any business, property or rights of Borrower (i) which involve any Loan
Document or (ii) as to which there is a reasonable possibility of an adverse determination and
which, if adversely determined, would reasonably be expected to, individually or in the aggregate,
result in a Material Adverse Effect.

5.6 Laws. Borrower is not in violation of any law, rule or regulation, or in default
with respect to any judgment, writ, injunction or decree of any governmental authority, where such
violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is
not in default in any manner under any provision of any indenture or other agreement, contract or
instrument evidencing Indebtedness, or any other material agreement, contract or instrument to
which it is a party or by which it or any of its properties or assets are or may be bound and for
which such default would reasonably be expected to result in a Material Adverse Effect.

5.7 Information Correct. The financial projections that have been provided by
Borrower to Lender were prepared by Borrower in good faith and were based on assumptions that were
reasonable when made, and the summaries of Borrower’s material contracts that have been provided by
Borrower to Lender are accurate summaries, in all material respects of the material terms of those
contracts. All other written information delivered by Borrower to Lender in connection with the
Loan Documents on or prior to the date hereof, taken as a whole with all information provided to
Lender by Borrower, did not contain, at the time such written information was delivered, any untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading.

5.8 Tax Matters. Except as described on Schedule 5.8, (a) Borrower has filed
all federal, state and local tax returns that it is required to file, (b) Borrower has duly paid or
fully reserved for all taxes or installments thereof (including any interest or penalties) as and
when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully
reserved for any tax assessment received by Borrower for the three (3) years preceding the Closing
Date, if any (including any taxes being contested in good faith and by appropriate proceedings).

5.9 Intellectual Property Claims. To the Borrower’s knowledge, except as set forth on
Schedule 5.9, the Borrower is the sole owner of, or otherwise has the right to use, all
Intellectual Property used in, or necessary for, the operation or conduct of its business as of the
date hereof. To the Borrower’s knowledge, no claim has been made that any Intellectual Property
violates the rights of any third party, except to the extent such claim would not reasonably be
expected to have a Material Adverse Effect. Borrower is not in material breach of, nor has
Borrower failed to perform any material obligations under, any material agreement under which
Borrower licenses Intellectual Property from third parties (other than shrink-wrap software
licenses and other licenses which if terminated could not reasonably be expected to result in a
Material Adverse Effect) and, to Borrower’s knowledge, no third party to any such agreement is in
material breach thereof or has failed to perform any material obligations thereunder.

5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower
has the right to freely (i) transfer, license or assign all material Intellectual Property that is
owned by the Borrower, and (ii) transfer or sublicense all material Intellectual Property that is
licensed to the Borrower, in each case without condition, restriction or payment of any kind to any
third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software
development tools, library functions, compilers and all other third-party software and other items
that are used in the design, development, promotion, sale, license, manufacture, import, export,
use or distribution of Borrower Products.

5.11 [RESERVED]

5.12 Borrower Products. No Intellectual Property owned by Borrower and no Borrower
Product has been or is subject to any actual or, to the knowledge of Borrower, threatened in
writing litigation, proceeding (including any proceeding in the United States Patent and Trademark
Office or any corresponding foreign office or agency) or outstanding decree, order, judgment,
settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or
licensing thereof or that may affect the validity, use or enforceability thereof. There is no
decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in
connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership
interest in any future Intellectual Property related to the operation or conduct of the business of
Borrower or Borrower Products.

5.13 Financial Accounts. Schedule 5.13 sets forth a true, correct and
complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary
maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains
an account holding Investment Property, and such exhibit correctly identifies the name, address and
telephone number of each bank or other institution, the name in which the account is held and the
complete account number therefor.

5.14 Employee Loans. Except with respect to reimbursement of expenses of employees,
officers or directors in the ordinary course of business, Borrower has no outstanding loans to any
employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan
made to an employee, officer or director of the Borrower by a third party.

5.15 Capitalization. Borrower’s capitalization is set forth on Schedule 5.15
annexed hereto. Borrower does not own any stock, partnership interest or other equity securities
of any Person, except for Permitted Investments. Attached as Schedule 5.15 hereto is a true,
correct and complete list of each Subsidiary.

ARTICLE 6 INSURANCE; INDEMNIFICATION

6.1 Coverage. So long as there are any non-contingent Secured Obligations
outstanding: (i) Borrower shall cause to be carried and maintained commercial general liability
insurance, on an occurrence form, against risks customarily insured against in Borrower’s line of
business and such risks shall include the risks of bodily injury, including death, property damage,
personal injury, and contractual liability per the terms of the indemnification agreement set forth
in Section 6.3; (ii) Borrower must maintain a minimum of Two Million Dollars ($2,000,000.00) of
commercial general liability insurance for each occurrence; (iii) Borrower must maintain a minimum
of $5,000,000 of directors and officers’ insurance for each occurrence, and $10,000,000 in the
aggregate; (iv) Borrower shall cause to be carried and maintained insurance upon the Collateral,
insuring against all risks of physical loss or damage howsoever caused, in an amount not less than
the full replacement cost of the Collateral; and (vi) Borrower shall carry and maintain a fidelity
insurance policy in an amount not less than $150,000.

6.2 Certificates. Borrower shall deliver to Lender certificates of insurance that
evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations
contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an
additional insured for commercial general liability, an additional insured and a loss payee for all
risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity
insurance, and a loss payee for property insurance and additional insured for liability insurance
for any future insurance that Borrower may acquire from such insurer. Attached to the certificates
of insurance will be additional insured endorsements for liability and lender’s loss payable
endorsements for all risk property damage insurance and fidelity. All certificates of insurance
will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation or
any other change adverse to Lender’s interests. Any failure of Lender to scrutinize such insurance
certificates for compliance is not a waiver of any of Lender’s rights, all of which are reserved.
Unless an Event of Default has occurred and is continuing, all payments under any such policy of
insurance shall be paid (either directly or through the Lender) to the Borrower.

6.3 Indemnity. Borrower shall and does hereby indemnify and hold Lender, its
officers, directors, employees, agents, in-house attorneys, representatives and shareholders
harmless from and against any and all claims, costs, expenses, damages and liabilities (including
such claims, costs, expenses, damages and liabilities based on liability in tort, including strict
liability in tort), including reasonable attorneys’ fees and disbursements and other costs of
investigation or defense (including those incurred upon any appeal), that may be instituted or
asserted against or incurred by Lender or any such Person as the result of credit having been
extended, suspended or terminated under this Agreement and the other Loan Documents or the
administration of such credit, or in connection with or arising out of the transactions
contemplated hereunder and thereunder, or any actions or failures to act in connection therewith,
or arising out of the disposition or utilization of the Collateral, excluding in all cases claims
resulting solely from Lender’s or any indemnified party’s gross negligence, willful misconduct or
breach of Lender’s obligations hereunder. Borrower agrees to pay, and to save Lender harmless
from, any and all liabilities with respect to, or resulting from any delay in paying, any and all
excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of
Lender) that may be payable or determined to be payable with respect to any of the Collateral or
this Agreement.

	 	 	 
	ARTICLE 7

	 	COVENANTS OF BORROWER
	 
	 	 
	Borrower agrees as follows, for so long as any Loans are outstanding:

	 
	 	 
	7.1

	 	Financial Reports and Other Information. Borrower shall furnish to Lender:
	
 
	 	 

(a) the Compliance Certificate in the form of Exhibit F monthly within 30 days
after the end of each month;

(b) as soon as practicable (and in any event within 30 days) after the end of each
month beginning with March 2007, Borrower’s unaudited internally-prepared and reported
balance sheet and related statements of income and cash flows as of the end of such month,
which shall be prepared in good faith based on the books and records of the Company but in
any event do not need to be prepared in accordance with GAAP and certified to such effect by
Borrower’s Chief Executive Officer, Chief Financial Officer, or Vice President/Controller;

(c) as soon as practicable (and in any event within 5 days of filing and no later than
45 days after the end of each of the first three calendar quarters of each year), the
Borrower’s unaudited interim financial statements as of the end of such calendar quarter
(prepared on a consolidated and consolidating basis, if applicable), including balance sheet
and related statements of income and cash flows, in each case prepared in accordance with
GAAP, consistently applied, as of the end of, and for such period (subject to normal year
end audit adjustments and the omission of footnotes) and certified by Borrower’s Chief
Executive Officer, Chief Financial Officer or Vice President/Controller;

(d) as soon as practicable (and in any event within 90 days) after the end of each
fiscal year, Borrower’s unqualified audited financial statements as of the end of such year
(prepared on a consolidated and consolidating basis, if applicable), including balance sheet
and related statements of income and cash flows, and setting forth in comparative form the
corresponding figures for the preceding fiscal year, prepared in accordance with GAAP,
consistently applied, as of the end of, and for such period, and reported on by KPMG LLP or
other independent certified public accountants of nationally recognized standing;

(e) promptly after the sending or filing thereof, as the case may be, copies of any
proxy statements, financial statements or reports that Borrower has made available to
holders of its Common Stock and copies of any annual, quarterly or current reports or
registration statements that Borrower files with the Securities and Exchange Commission or
any governmental authority that may be substituted therefor; and

(f) budgets, operating plans and other financial information reasonably requested by
Lender in writing.

Except as set forth in the immediately succeeding sentence, any document required to be delivered
pursuant to this Section 7.1 may be sent via facsimile to Lender at (866) 468-8916 or via e-mail to
financialstatements@herculestech.com. All financial statements required to be delivered pursuant
to clauses (b), (c) and (d) shall be sent via e-mail to
financialstatements@herculestech.com with a copy to pshah@herculestech.com
provided, that if e-mail is not available or sending such financial statements via e-mail
is not practicable, they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief
Credit Officer, reference Memory Pharmaceuticals Corp.

7.2 Management Rights. Borrower shall permit any representative that Lender
authorizes, including its attorneys and accountants, to inspect the Collateral, examine and make
copies and abstracts of the books of account and records of Borrower at reasonable times and upon
reasonable notice during normal business hours. In addition, any such representative shall have
the right to meet with management and officers of Borrower to discuss such books of account and
records at reasonable times and upon reasonable notice during normal business hours. Such
consultations shall not unreasonably interfere with Borrower’s business operations. The parties
intend that the rights granted Lender shall constitute “management rights” within the meaning of 29
C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender
with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise
by Lender of, control over Borrower’s management or policies.

7.3 Further Assurances. Borrower shall from time to time execute, deliver and file,
alone or with Lender, any financing statements, security agreements, collateral assignments,
notices, control agreements, or other documents to perfect or give the highest priority (other than
with respect to Permitted Liens) to Lender’s Lien on the Collateral. Borrower shall from time to
time procure any instruments or documents as may be requested by Lender, and take all further
action that may be necessary or desirable, or that Lender may reasonably request, to perfect and
protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower
hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing
statements, collateral assignments, notices, control agreements, security agreements and other
documents without the signature of Borrower either in Lender’s name or in the name of Lender as
agent and attorney-in-fact for Borrower. Borrower shall protect and defend Borrower’s title to the
Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower
or Lender.

7.4 [RESERVED]

7.5 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain
liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted
Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation
to prepay any Indebtedness, other than Permitted Indebtedness.

7.6 Collateral. Borrower shall, and shall cause each subsidiary to, at all times keep
the Collateral and all other property and assets used in Borrower’s or such subsidiary’s business
or in which Borrower or such subsidiary now or hereafter holds any interest free and clear of any
Liens (except for Permitted Liens), and shall give Lender prompt written notice of any legal
process affecting the Collateral, such other property and assets, or any Liens (other than
Permitted Liens) thereon.

7.7 Encumbrances on Intellectual Property. Expect in connection with a Collaboration
(but not in any case in connection with the incurrence of Indebtedness) or Permitted Liens,
Borrower will not (i) create, incur, assume or allow to exist any Lien to secure Indebtedness on
its Intellectual Property; (ii) assign or otherwise convey to a third party any of its Intellectual
Property; or (iii) covenant to any other Person that Borrower in the future will refrain from
creating, incurring, assuming or allowing any Lien with respect to any of its Intellectual
Property.

7.8 Investments. Borrower shall not directly or indirectly acquire or own, or make
any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than
Permitted Investments.

7.9 Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a)
repurchase or redeem any class of stock or other equity interest other than pursuant to employee,
director or consultant repurchase plans or other similar agreements, provided, however, in
each case the repurchase or redemption price does not exceed the original consideration paid for
such stock or equity interest, or (b) declare or pay any cash dividend or make a cash distribution
on any class of stock or other equity interest, or (c) lend money to any employees, officers or
directors or guarantee the payment of any such loans granted by a third party in excess of $100,000
in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers
or directors in excess of $100,000 in the aggregate.

7.10 Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or
involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable,
beneficial or legal interest in any material portion of its assets.

7.11 Taxes. Borrower and its Subsidiaries shall pay when due all taxes, fees or other
charges of any nature whatsoever (together with any related interest or penalties) now or hereafter
imposed or assessed against Borrower, Lender or the Collateral or upon Borrower’s ownership,
possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings
arising therefrom; provided, however, that in no event shall Borrower be liable for any taxes
related to the income of Lender. Borrower shall file on or before the due date therefor all
personal property tax returns in respect of the Collateral. Notwithstanding the foregoing,
Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower
maintains adequate reserves therefor in accordance with GAAP.

7.12 Corporate Changes. Neither Borrower nor any Subsidiary shall change its
corporate name, legal form or jurisdiction of formation without twenty (20) days’ prior written
notice to Lender. Neither Borrower nor any Subsidiary shall relocate its chief executive office or
its principal place of business unless: (i) it has provided prior written notice to Lender; and
(ii) such relocation shall be within the continental United States. Neither Borrower nor any
Subsidiary shall relocate any item of Collateral (other than (x) sales of Inventory in the ordinary
course of business, (y) relocations of equipment having an aggregate value of up to $150,000 in any
fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another
location described on Exhibit C) unless (i) it has provided prompt written notice to Lender and
(ii) such relocation is within the continental United States.

7.13 Payments. Lender will initiate debit entries to the Borrower’s account as
authorized on the ACH Debit Authorization Agreement in the form of Exhibit H on each Payment Date
of all periodic obligations payable to Lender under each Note or Advance.

7.14 Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit
Accounts, or accounts holding Investment Property, except with respect to which Lender has a
perfected security interest in each such account. Notwithstanding the foregoing, Lender
acknowledges that Borrower maintains account no. with JP Morgan Chase Bank (the “Funds Account”),
which is not subject to an account control agreement. Borrower represents that it has not signed
any agreement with any other Person (other than JP Morgan Chase Bank) giving that Person control
over, or a security interest in, the Funds Account. Within 3 Business Days after the Closing Date,
Borrower will transfer assets worth at least $25,000,000 from the Funds Account to an account that
is subject to a mutually acceptable account control agreement. Within 90 days after the Closing
Date, Borrower will transfer the balance of the assets in the Funds Account to an account that is
subject to a mutually acceptable control agreement, and will close the Funds Account.

	 	 	 
	ARTICLE 8

ARTICLE 9

	 	RESERVED.

EVENTS OF DEFAULT.

The occurrence of any one or more of the following events shall be an Event of Default:

9.1 Payments. Borrower fails to pay any amount of principal or interest due under
this Agreement or the Notes on the due date (except as a result of Lender failing to comply with
Section 7.13); or

9.2 Covenants. Borrower breaches or defaults in any material respect in the
performance of any covenant or Secured Obligation under this Agreement, the Notes, or any of the
other Loan Documents, and (a) with respect to a default under any covenant under this Agreement
(other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8. 7.9 or 7.10) such default continues for more
than twenty (20) days after the earlier of the date on which (i) Lender has given written notice of
such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect
to a default under any of Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.10, the occurrence of such
default; or

9.3 Material Adverse Effect. An event occurs or circumstance exists that has had a
Material Adverse Effect and such Material Adverse Effect continues for more than 10 days after the
date on which Lender gives written notice to Borrower specifying in reasonable detail the basis for
its determination that such event or circumstance has had a Material Adverse Effect.

9.4 Other Loan Documents. The failure by the Borrower to comply in any material
respect with the covenants contained in any Loan Document or any agreement between Borrower and
Lender (other than the Warrant) and such default continues for more than ten (10) days after the
earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual
knowledge of such default; or

9.5 Representations. Any representation or warranty made by Borrower in any Loan
Document shall have been false or misleading in any material respect when made or deemed made; or

9.6 Insolvency. Borrower (a) shall make an assignment for the benefit of creditors;
or (b) shall admit in writing its inability to pay its debts as they become due, or its inability
to pay or perform under the Loan Documents; or (c) shall file a voluntary petition in bankruptcy;
or (d) shall file any petition, answer, or document seeking for itself any reorganization,
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any
present or future statute, law or regulation pertinent to such circumstances; or (e) shall seek or
consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or
of all or any substantial part (i.e. 33-1/3% or more) of the assets or property of Borrower; or (f)
shall cease operations of its business as its business has normally been conducted, or terminate
substantially all of its employees, or becomes insolvent; or (g) Borrower or its directors or
majority shareholders shall take any action initiating any of the foregoing actions described in
clauses (a) through (f); or either (a) 60 days shall have expired after the commencement of an
involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment,
liquidation, dissolution or similar relief under any present or future statute, law or regulation,
without such action being dismissed or all orders or proceedings thereunder affecting the
operations or the business of Borrower being stayed; or (b) a stay of any such order or proceedings
shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (c)
Borrower shall file any answer admitting or not contesting the material allegations of a petition
filed against Borrower in any such proceedings; or (d) the court in which such proceedings are
pending shall enter a decree or order granting the relief sought in any such proceedings; or 60
days shall have expired after the appointment, without the consent or acquiescence of Borrower, of
any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties
of Borrower without such appointment being vacated; or

9.7 Attachments; Judgments. Any portion of Borrower’s assets having a fair market
value in excess of $250,000 is attached or seized, or a levy is filed against any such assets, or a
final judgment or judgments is/are entered for the payment of money, individually or in the
aggregate, of at least $250,000 (exclusive of amounts covered by insurance as to which the insurer
has acknowledged coverage) or Borrower is enjoined or in any way prevented by court order from
conducting any material part of its business, and the such attachment, levy, judgment or injunction
shall not have been discharged, bonded or a stay of execution thereof shall not have been procured,
within 60 days from the date of entry thereof and the Borrower shall not, within such 60 day
period, or such longer period during which execution of the same shall have been stayed, appeal
therefrom and cause the execution thereof to be stayed during such appeal; or

9.8 Other Obligations. The occurrence of any default under any agreement or
obligation of Borrower involving any obligation in excess of $100,000 that, when aggregated with
any other such defaults, would reasonably be expected to have a Material Adverse Effect.

ARTICLE 10 REMEDIES

10.1 General. Upon and during the continuance of any one or more Events of Default,
(i) Lender may, at its option, accelerate and demand payment of all or any part of the outstanding
Secured Obligations and declare them to be immediately due and payable (provided, that upon
the occurrence of an Event of Default of the type described in Section 9.6, the Notes and all of
the outstanding Secured Obligations shall automatically be accelerated and made due and payable, in
each case without any further notice or act), (ii) Lender may notify any of Borrower’s account
debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s
behalf and endorse Lender’s name without recourse on any such payment for deposit directly to
Lender’s account and (iii) Lender may exercise all rights and remedies with respect to the
Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable
law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or
otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process
and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not
exclusive.

10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any
Event of Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in
one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then
condition or following any commercially reasonable preparation or processing, in such order as
Lender may elect. Any such sale may be made either at public or private sale at its place of
business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten
(10) calendar days’ prior written notice to Borrower. Lender may require Borrower to assemble the
Collateral and make it available to Lender at a place designated by Lender that is reasonably
convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon
all or any part of the Collateral shall be applied by Lender in the following order of priorities:

First, to Lender in an amount sufficient to pay in full Lender’s
costs and professionals’ and advisors’ fees and expenses as described in
Section 11.11;

Second, to Lender in an amount equal to the then unpaid amount of
the Secured Obligations (including principal, interest, and the Default Rate
interest), in such order and priority as Lender may choose in its sole
discretion; and

Finally, after the full, final, and indefeasible payment in Cash of all of
the Secured Obligations, or to Borrower or its representatives or as a court
of competent jurisdiction may direct.

Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any
of the Collateral if it complies with the obligations of a secured party under the UCC.

10.3 No Waiver. Lender shall be under no obligation to marshal any of the Collateral
for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any,
to require Lender to marshal any Collateral.

10.4 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall
be in addition to all rights, powers and remedies given by statute or rule of law and are
cumulative. The exercise of any one or more of the rights, powers and remedies provided herein
shall not be construed as a waiver of or election of remedies with respect to any other rights,
powers and remedies of Lender.

ARTICLE 11 MISCELLANEOUS

11.1 Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement shall be prohibited by or invalid under such law, such provision shall be
ineffective only to the extent and duration of such prohibition or invalidity, without invalidating
the remainder of such provision or the remaining provisions of this Agreement.

11.2 Notice. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, or other communication (including the delivery of Financial
Statements) that is required, contemplated, or permitted under the Loan Documents or with respect
to the subject matter hereof shall be in writing, and shall be deemed to have been validly given,
delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand
delivery or deposit with an overnight express service or overnight mail delivery service; or (ii)
the third calendar day after deposit in the United States mails, with proper first class postage
prepaid, in each case addressed to the party to be notified as follows:

(a) If to Lender:

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

Legal Department

Attention: Chief Legal Officer and Parag Shah

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Facsimile: 650- 473-9194

Telephone: 650-289-3068

(b) If to Borrower:

MEMORY PHARMACEUTICALS, CORP.

100 Philips Parkway

Montvale, NJ 07645

Attention: Mike Smith

Facsimile: 201-802-7190

Telephone: 201-802-7100

with a copy to:

MEMORY PHARMACEUTICALS, CORP.

100 Philips Parkway

Montvale, NJ 07645

Attention: Jzaneen Lalani, Esq.

Facsimile: 201-802-7190

Telephone: 201-802-7100

or to such other address as each party may designate for itself by like notice.

11.3 Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan
Documents constitute the entire agreement and understanding of the parties hereto in respect of the
subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals,
term sheets, letters, negotiations or other documents or agreements, whether written or oral, with
respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated
December 20, 2006). None of the terms of this Agreement, the Notes or any of the other Loan
Documents may be amended except by an instrument executed by each of the parties hereto.

11.4 No Strict Construction. The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or
interpretation arises, this Agreement shall be construed as if drafted jointly by the parties
hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement.

11.5 No Waiver. The powers conferred upon Lender by this Agreement are solely to
protect its rights hereunder and under the other Loan Documents and its interest in the Collateral
and shall not impose any duty upon Lender to exercise any such powers. No omission or delay by
Lender at any time to enforce any right or remedy reserved to it, or to require performance of any
of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver
of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right
of Lender to enforce such provisions thereafter.

11.6 Survival. All agreements, representations and warranties contained in this
Agreement, the Notes and the other Loan Documents or in any document delivered pursuant hereto or
thereto shall be for the benefit of Lender and shall survive the execution and delivery of this
Agreement and the expiration or other termination of this Agreement.

11.7 Successors and Assigns. The provisions of this Agreement and the other Loan
Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if
any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the
other Loan Documents without Lender’s express prior written consent, and any such attempted
assignment shall be void and of no effect.

11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been
negotiated and delivered to Lender in the State of California, and shall have been accepted by
Lender in the State of California. Payment to Lender by Borrower of the Secured Obligations is due
in the State of California. This Agreement, the Notes and the other Loan Documents shall be
governed by, and construed and enforced in accordance with, the laws of the State of California,
excluding conflict of laws principles that would cause the application of laws of any other
jurisdiction.

11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that
the reference requirement of Section 11.10 is not applicable) arising in or under or related to
this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal
court located in the State of California. By execution and delivery of this Agreement, each party
hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa
Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa
Clara County, State of California; (c) agrees not to assert any defense based on lack of
jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any
judgment rendered thereby in connection with this Agreement, the Notes or the other Loan Documents.
Service of process on any party hereto in any action arising out of or relating to this Agreement
shall be effective if given in accordance with the requirements for notice set forth in Section
11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein
shall affect the right to serve process in any other manner permitted by law or shall limit the
right of either party to bring proceedings in the courts of any other jurisdiction.

11.10 Mutual Waiver of Jury Trial / Judicial Reference.

(a) Because disputes arising in connection with complex financial transactions are most
quickly and economically resolved by an experienced and expert person and the parties wish
applicable state and federal laws to apply (rather than arbitration rules), the parties desire that
their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND LENDER
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM,
CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED
BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This
waiver extends to all such Claims, including Claims that involve Persons other than Borrower and
Lender; Claims that arise out of or are in any way connected to the relationship between Borrower
and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any
equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.

(b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable,
the parties agree that all Claims shall be resolved by reference to a private judge sitting without
a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or,
if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County,
California. Such proceeding shall be conducted in Santa Clara County, California, with California
rules of evidence and discovery applicable to such proceeding.

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a
court identified in Section 11.10, any prejudgment order, writ or other relief and have such
prejudgment order, writ or other relief enforced to the fullest extent permitted by law
notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses
necessary to finalize the loan documentation, including but not limited to reasonable attorneys
fees, UCC searches, filing costs, and other miscellaneous expenses upon presentation of reasonable
documentation or invoices; provided, however, that the Commitment Fee shall be credited against the
Lender’s non-legal transaction costs and due diligence expenses. In addition, Borrower promises to
pay any and all reasonable attorneys’ and other professionals’ fees and expenses incurred by Lender
after the Closing Date in connection with or related to: (a) the collection or enforcement of the
Loan; (b) the amendment or modification of the Loan Documents (to the extent such amendment or
modification is requested by the Borrower); (c) any waiver, consent, release, or termination under
the Loan Documents; (d) the protection, preservation, sale, lease, liquidation, or disposition of
Collateral or the exercise of remedies with respect to the Collateral; (e) any legal, litigation,
administrative, arbitration, or out of court proceeding in connection with or related to Borrower
or the Collateral, and any appeal or review thereof; and (f) any bankruptcy, restructuring,
reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action
related to Borrower, the Collateral, the Loan Documents, including representing Lender in any
adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s
estate, and any appeal or review thereof.

11.12 Confidentiality. Lender acknowledges that certain items of Collateral,
Intellectual Property of the Borrower and information provided to Lender by Borrower are
confidential and proprietary information of Borrower, (the “Confidential Information”).
Accordingly, Lender agrees that any Confidential Information it may obtain in the course of
acquiring, administering, or perfecting Lender’s security interest in the Collateral shall not be
disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the
prior written consent of Borrower, except that Lender may disclose any such information: (a) to
its own directors, officers, employees, accountants, counsel and other professional advisors and to
its Affiliates if Lender in its sole discretion determines that any such party should have access
to such information in connection with such party’s responsibilities in connection with the Loan or
this Agreement and, provided that such recipient of such Confidential Information either (i) agrees
to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to
confidentiality restrictions that reasonably protect against the disclosure of Confidential
Information; (b) if such information is generally available to the public; (c) if required in any
report, statement or testimony submitted to any governmental authority having jurisdiction over
Lender; (d) in response to any summons or subpoena or in connection with any litigation, to the
extent Lender’s counsel advises that such disclosure is legally required; (e) to comply with any
legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection
with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease,
or other disposition of Collateral after default; (g) to any participant or assignee of Lender or
any prospective participant or assignee; provided, that such participant or assignee or
prospective participant or assignee agrees in writing to be bound by this Section prior to
disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any
disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any
of its Affiliates or any guarantor under this Agreement or the other Loan Documents.

11.13 Assignment of Rights. Lender may sell and assign all or part of its interest
hereunder and under the Note(s) and Loan Documents (a) to any Affiliate of Lender servicing the
Loan in connection with the Note Purchase Agreement among Hercules Funding Trust I, Hercules
Funding I LLC, Hercules Technology Growth Capital, Inc. and Citigroup Global Markets Realty Corp.,
dated as of August 1, 2005, (b) to any Affiliate of Lender licensed by the U.S. Small Business
Administration, (c) as collateral security to Lender’s senior secured lender to the extent required
under the applicable loan agreement, and (d) in connection with any securitization undertaken by
Lender and/or its Affiliates, provided that Lender or an Affiliate of Lender continues to service
the Loan (each of (a), (b), (c) and (d), being a “Permitted Assignee”), . After such assignment,
the term “Lender” as used in the Loan Documents shall mean and include such Permitted Assignee, and
such Permitted Assignee shall be vested with all rights, powers and remedies of Lender hereunder
with respect to the interest so assigned; but with respect to any such interest not so transferred,
Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender
shall relieve Borrower of any of its obligations hereunder. Lender agrees that in the event of any
transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the
principal of the Note(s), which shall have been paid at the time of such transfer and as to the
date to which interest shall have been last paid thereon. Other than to a Permitted Assignee, no
sale or assignment by Lender of all or any part of the Note(s) or Loan Documents shall be permitted
under this Agreement without the prior written consent of Borrower, provided that after the
occurrence and during the continuation of an Event of Default, Lender may sell or assign all or any
part of its interest hereunder and under the Note(s) and Loan Documents to any Person without the
consent of Borrower.

11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall
remain in full force and effect and continue to be effective if any petition is filed by or against
Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment
for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part
of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The
Loan Documents and the Secured Obligations and Collateral security shall continue to be effective,
or shall be revived or reinstated, as the case may be, if at any time payment and performance of
the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded,
avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is
recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable
preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or
transfer of Collateral had not been made. In the event that any payment, or any part thereof, is
rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and
the Secured Obligations shall be deemed, without any further action or documentation, to have been
revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender
in Cash.

11.15 Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto
in separate counterparts, each of which when so delivered shall be deemed an original, but all of
which counterparts shall constitute but one and the same instrument.

11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended,
nor will be interpreted, to provide or create any third-party beneficiary rights or any other
rights of any kind in any person other than Lender and Borrower unless specifically provided
otherwise herein, and, except as otherwise so provided, all provisions of the Loan
Documents will be personal and solely between the Lender and the Borrower.

11.17 Specific Performance. The parties hereto hereby declare that it is impossible
to measure in money the damages which will accrue to Lender by reason of Borrower’s failure to
perform any of the obligations under this Agreement and agree that the terms of this Agreement
shall be specifically enforceable by Lender. If Lender institutes any action or proceeding to
specifically enforce the provisions hereof, any Person against whom such action or proceeding is
brought hereby waives the claim or defense therein that Lender has an adequate remedy at law, and
such Person shall not offer in any such action or proceeding the claim or defense that such remedy
at law exists.

11.18 Publicity. Lender may use Borrower’s name and logo, and include a brief
description of the relationship between Borrower and Lender, in Lender’s marketing materials in a
form to be mutually agreed by Lender and Borrower.

11.19 Termination and Release. When all the non-contingent Secured Obligations have
been paid in full and have been terminated and the obligation of the Lender to make any Advances
hereunder has terminated or expired, this Agreement and the first priority security interest in the
Collateral created hereby shall terminate and all rights to the Collateral shall automatically
revert to the Borrower, all without delivery of any instrument or performance of any act by any
party. If any of the Collateral shall be sold, transferred or otherwise disposed of by the
Borrower in a transaction permitted hereby or in a transaction with respect to which any written
consent to the release of any Lien created hereunder in respect of any Collateral has been
obtained, the Lien created pursuant to this Agreement on such Collateral shall be automatically
released, all without delivery of any instrument or performance of any act by any party. In
connection with any release or termination referred to in this Section 11.19, the Lender agrees to
execute appropriate releases of liens on the Collateral upon the request of the Borrower and at the
Borrower’s expense.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

1

IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written.

	 	 	 
	BORROWER:	 	MEMORY PHARMACEUTICALS CORP.
	
 
	 	Signature: /s/ James R. Sulat
	
 
	 	 
	
 
	 	Print Name: James R. Sulat

Title: President and Chief Executive Officer
	 
	 	 
	Accepted in Palo Alto, California:

	 	

	 

	 	

	 
	 	 
	LENDER:

	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

Signature: /s/ Scott Harvey
	
 
	 	 

	 	 	Print Name: Scott Harvey

Title: Chief Legal Officer

2

Table of Exhibits and Schedules

	 	 	 
	Exhibit A:

Exhibit B:

Exhibit C:

Exhibit D:

Exhibit E:

Exhibit F

Exhibit G:

Exhibit H:

Exhibit I:

	 	Advance Request

Attachment to Advance Request

Promissory Note

Name, Locations, and Other Information for Borrower

Reserved

Reserved

Compliance Certificate

Joinder Agreement

ACH Debit Authorization Agreement

Form of Warrant

3

EXHIBIT A

ADVANCE REQUEST

	 	 	 	 	 	 	 	 	 	 	 	 	 
	To:
	 	Lender:
	 	Date:
	 	 	__________, 20___	 
	 
	 	Hercules Technology Growth Capital, Inc.
	 	 	 	 	 	 	 	 
	 
	 	400 Hamilton Avenue, Suite 310	 	 	 	 	 	 	 	 
	 
	 	Palo Alto, CA 94301
	 	 	 	 	 	 	 	 
	 
	 	Facsimile:  650-473-9194
	 	 	 	 	 	 	 	 
	 
	 	Attn:
	 	 	 	 	 	 	 	 

MEMORY PHARMACEUTICALS, CORP. (“Borrower”) hereby requests from Hercules Technology Growth Capital,
Inc. (“Lender”) an Advance in the amount of      Dollars ($     ) on
     ,      (the “Advance Date”) pursuant to the Loan and Security Agreement between
Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise
defined herein are used with the same meanings as defined in the Agreement.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Please:
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	(a	)	 	Issue a check payable to Borrower________

	 
	 	 	 	 	 	 	 	 	 	or

	 	 	 	(b	)	 	Wire Funds to Borrower’s account________

	 
	 	 	 	 	 	Bank:
	 	 	—	 
	 
	 	 	 	 	 	Address:
	 	 	—	 

     

	 	 	 	 	 
	ABA Number:
	 	 	—	 
	Account Number:___________________________

	Account Name:
	 	 	—	 

Borrower represents that the conditions precedent to the Advance set forth in the Agreement
are satisfied on and as of the date hereof, including but not limited to: (i) that no Material
Adverse Effect shall have occurred and be continuing; (ii) that the representations and warranties
set forth in the Agreement are true and correct in all material respects on and as of the date
hereof with the same effect as though made on and as of such date, except to the extent such
representations and warranties expressly relate to an earlier date; (iii) that Borrower is in
compliance in all material respects with all the terms and provisions set forth in each Loan
Document on its part to be observed or performed; and (iv) that as of the Advance Date, no fact or
condition exists that would (or would, with the passage of time, the giving of notice, or both)
constitute an Event of Default under the Loan Documents.

Borrower hereby represents that Borrower’s corporate status and locations have not changed
since the date of this Agreement of, if the Attachment to this Advance Request is completed, are as
set forth in the Attachment to this Advance Request.

Borrower agrees to notify Lender promptly before the funding of the Loan if any of the matters
which have been represented above shall not be true and correct on the Advance Date and if Lender
has received no such notice before the Advance Date then the statements set forth above shall be
deemed to have been made and shall be deemed to be true and correct as of the Advance Date.

Executed as of      , 20     .

4

	 	 	 	 	 
	BORROWER: MEMORY PHARMACEUTICALS CORP.

	SIGNATURE: ________________________________________

	TITLE:
	 	Chief Executive Officer or Vice President/Controller

	PRINT NAME:
	 	 	—	 

5

ATTACHMENT TO ADVANCE REQUEST

Dated: _______________________

Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational
status is as follows:

	 	 	 
	Name:

Type of organization:

State of organization:

Organization file number:

	 	MEMORY PHARMACEUTICALS CORP.

Corporation

Delaware

	
 
	 	 

Borrower hereby represents and warrants to Lender that the street addresses, cities, states and
postal codes of its current locations are as follows:

6

EXHIBIT B

SECURED PROMISSORY NOTE

	 	 	 
	$     ,000,000

	 	Advance Date:      , 20     

FOR VALUE RECEIVED, MEMORY PHARMACEUTICALS CORP., a Delaware corporation, for itself and each
of its Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology
Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400
Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of
this Secured Promissory Note (this “Promissory Note”) may specify from time to time in writing, in
lawful money of the United States of America, the principal amount of      
($     ,000,000) or such other principal amount as Lender has advanced to Borrower, together with
interest at a fixed rate equal to the prime rate as reported in the Wall Street Journal, and if not
reported, then the prime rate next reported in the Wall Street Journal, plus 3.2% per annum based
upon a year consisting of 360 days, with interest computed daily based on the actual number of days
in each month.

This Promissory Note is the Note or one of a series of Notes referred to in, and is executed
and delivered in connection with, that certain Loan and Security Agreement dated March 16, 2007, by
and between Borrower and Lender (as the same may from time to time be amended, modified or
supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit
and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement),
to which reference is made for a statement of all of the terms and conditions thereof. All
payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan
Agreement shall have the same definitions when used herein, unless otherwise defined herein. An
Event of Default under the Loan Agreement shall constitute a default under this Promissory Note.
Reference to the Loan Agreement shall not affect or impair the absolute and unconditional
obligation of the Borrowers to pay all principal and interest and premium, if any, under this
Promissory Note upon demand or as otherwise provided herein

Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of
protest under the UCC or any applicable law. Borrower agrees to make all payments under this
Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or
defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the
State of California. This Promissory Note shall be governed by and construed and enforced in
accordance with, the laws of the State of California, excluding any conflicts of law rules or
principles that would cause the application of the laws of any other jurisdiction.

	 	 	 
	BORROWER FOR ITSELF AND

ON BEHALF OF ITS SUBSIDIARIES:

	 	

MEMORY PHARMACEUTICALS CORP.
	 
	 	 
	
 
	 	By:
	
 
	 	 
	
 
	 	Name:
	
 
	 	 
	
 
	 	Title:
	
 
	 	 

7

EXHIBIT C

NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER

1. Borrower represents and warrants to Lender that Borrower’s current name and organizational
status as of the Closing Date is as follows:

	 	 	 
	Name:

Type of organization:

State of organization:

Organization file number:

	 	MEMORY PHARMACEUTICALS CORP.

Corporation

Delaware

	
 
	 	 

2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing
Date, Borrower did not do business under any other name or organization or form except the
following:

Name:

Used during dates of:

Type of Organization:

State of organization:

Organization file Number:

Borrower’s fiscal year ends on      

Borrower’s federal employer tax identification number is:      

3. Borrower represents and warrants to Lender that its chief executive office is located at
     .

8

EXHIBIT D

RESERVED

9

EXHIBIT E

RESERVED

10

EXHIBIT F

COMPLIANCE CERTIFICATE

Hercules Technology Growth Capital, Inc.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Reference is made to that certain Loan and Security Agreement dated as of March 16, 2007 and
all ancillary documents entered into in connection with such Loan and Security Agreement, all as
may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”)
between Hercules Technology Growth Capital, Inc (“Hercules”) as Lender and MEMORY PHARMACEUTICALS
CORP. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same
meaning as defined in the Loan Agreement.

The undersigned (i) is an officer of the Company; (ii) is authorized to execute and deliver
this Compliance Certificate on behalf of the Company; and (iii) hereby certifies that (a) the
representations and warranties contained in Section 5 (other than Sections 5.2 and 5.4) of the Loan
Agreement are true and correct in all material respects as of the date of this Compliance
Certificate except to the extent they expressly relate to an earlier date and except, with respect
to representations set forth in any of Sections 5.1, 5.5, 5.8, 5.9, 5.10, 5.12, 5.13 or 5.15 only,
as set forth on Attachment 1 to this Compliance Certificate or in any SEC Document
previously delivered to the Lender, (b) the Company is in compliance in all material respects for
the period ended      with all covenants set forth in Section 7 of the Loan Agreement, and
(c) no Event of Default has occurred. [The undersigned further certifies that the [quarterly]
[annual] financial statements listed below, which are included in the Company’s      Report on Form
     , have been prepared in accordance with generally accepted accounting principles (except for the
absence of footnotes with respect to unaudited financial statements and subject to normal year end
adjustments) and are consistent from one period to the next except as set forth therein.] The
undersigned further certifies that the monthly financial statements listed below have been prepared
in good faith based on the books and records of the Company.

	 	 	 	 	 
	REPORTING REQUIREMENT	 	REQUIRED	 	CHECK IF ATTACHED
	Monthly Internally-Reported

Financial Statements

	 	

Monthly within 30 days
	 	

	 
	 	 	 	 
	Interim Financial Statements

	 	Quarterly for the

first three quarters

of each year within 5

days of filing or 45

days of quarter end
	 	

	 
	 	 	 	 
	Audited Financial Statements

	 	FYE within 90 days
	 	

Financial Statements Related to this Compliance Certificate:

Very Truly Yours,

	 	 	 	MEMORY PHARMACEUTICALS CORP.

	 	 	 	 	 
	By:
	 	 	—	 
	Name:
	 	 	—	 
	Its:
	 	 	—	 

11

EXHIBIT G

FORM OF JOINDER AGREEMENT

This Joinder Agreement (the “Joinder Agreement”) is made and dated as of      , 20     , and
is entered into by and between     ., a      corporation (“Subsidiary”), and
HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation, as a Lender.

RECITALS

A. Subsidiary’s Affiliate, MEMORY PHARMACEUTICALS CORP. (“Company”) desires to enter into
that certain Loan and Security Agreement dated March 16, 2007, with Lender, as such agreement may
be amended (the “Loan Agreement”), together with the other agreements executed and delivered in
connection therewith;

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from
Company’s execution of the Loan Agreement and the other agreements executed and delivered in
connection therewith;

AGREEMENT

NOW THEREFORE, Subsidiary and Lender agree as follows:

	1.	 	The recitals set forth above are incorporated into and made part of this Joinder Agreement.
Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.

	2.	 	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of
the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement)
under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no
duties, responsibilities or obligations to Subsidiary arising under or related to the Loan
Agreement or the other agreements executed and delivered in connection therewith. Rather, to
the extent that Lender has any duties, responsibilities or obligations arising under or
related to the Loan Agreement or the other agreements executed and delivered in connection
therewith, those duties, responsibilities or obligations shall flow only to Company and not to
Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a)
Agent or a Lender’s providing notice to Company in accordance with the Loan Agreement or as
otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a
Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c)
Subsidiary shall have no right to request an Advance or make any other demand on Agent or a
Lender.

12

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE TO JOINDER AGREEMENT]

	 	 	 	SUBSIDIARY:

	 	 	 	     .

By:

Name:

Title:

Address:

Telephone:      

Facsimile:      

	 	 	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

By:     

Name:     

Title:      

Address:

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060

13

EXHIBIT H

ACH DEBIT AUTHORIZATION AGREEMENT

Hercules Technology Growth Capital, Inc.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Re: Loan and Security Agreement dated March 16, 2007 between MEMORY PHARMACEUTICALS CORP.
(“Borrower”) and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”)

In connection with the above referenced Agreement, the Borrower hereby authorizes the Company to
initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account
indicated below. The Borrower authorizes the depository institution named below to debit to such
account.

	 	 	 
	DEPOSITORY NAME

	 	BRANCH
	 

	 	 
	 
	 	 
	CITY

	 	STATE AND ZIP CODE
	 

	 	 
	 
	 	 
	TRANSIT/ABA NUMBER

	 	ACCOUNT NUMBER
	 

	 	 

This authority will remain in full force and effect so long as any amounts are due under the
Agreement.

MEMORY PHARMACEUTICALS CORP.

By:      

Date:      

14

EXHIBIT I

FORM OF WARRANT

15EX-4.2

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY
BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.

WARRANT (“Warrant”)

To Purchase Shares of the Common Stock of

MEMORY PHARMACEUTICALS CORP.

Dated as of March 16, 2007 (the “Effective Date”)

	 	 	SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK.

For value received, MEMORY PHARMACEUTICALS CORP., a Delaware corporation (the
“Company”), hereby grants to Hercules Technology Growth Capital, Inc., a Maryland
corporation (the “Warrantholder”) the right, and the Warrantholder is entitled, upon the
terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the
Company, up to 598,086 fully paid and non-assessable shares (the “Warrant Shares”) of the
Common Stock (as defined below), at an Exercise Price equal to $2.09 per Share. This Warrant is
being issued pursuant to the terms of the Loan and Security Agreement of even date herewith between
the Company and the Warrantholder (the “Loan Agreement”). The number and Exercise Price of
the Warrant Shares are subject to adjustment as provided in Section 8. As used herein, the
following terms shall have the following meanings:

“Act” means the Securities Act of 1933, as amended.

“Charter” means the Company’s Certificate of Incorporation, as may be amended from
time to time.

“Common Stock” means the Company’s common stock, $0.001 par value per share.

“Merger Event” means a merger or consolidation involving the Company in which the
Company is not the surviving entity (other than a merger solely to effect a reincorporation
of the Company into another state), or in which the outstanding shares of the Company’s
capital stock are otherwise converted into or exchanged for shares of capital stock of
another entity and in which the stockholders of the Company immediately prior to such
consolidation or merger, will hold less than a majority of the outstanding shares of such
other entity immediately after such consolidation or merger.

“Purchase Price” means, with respect to any exercise of this Warrant, an amount
equal to the Exercise Price as of the relevant time multiplied by the number of shares of
Common Stock requested to be exercised under this Warrant pursuant to such exercise.

	 	 	SECTION 2. TERM OF THE WARRANT.

Except as otherwise provided for herein, the term of this Warrant and the right to purchase
Common Stock as granted herein shall commence on the Effective Date and shall end at 11:59 p.m.
(New York City time) on March 16, 2012.

	 	 	SECTION 3. EXERCISE OF THE PURCHASE RIGHTS.

The purchase rights set forth in this Warrant are exercisable by tendering to the Company at
its principal office a notice of exercise in the form attached hereto as Exhibit I (the
“Notice of Exercise”), duly completed and executed. Promptly upon receipt of the Notice of
Exercise and the payment of the Purchase Price in accordance with the terms set forth below, the
Company shall issue to the Warrantholder a certificate for the number of shares of Common Stock
purchased and shall execute the acknowledgment of exercise in the form attached hereto as
Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which
remain subject to future purchases, if any. Notwithstanding the foregoing, this Warrant shall not
be exercisable during the Trigger Period.

The Purchase Price may be paid at the Warrantholder’s election either (i) by cash, check or
wire transfer of immediately available funds, or (ii) by surrender of all or a portion of the
Warrant for shares of Common Stock to be exercised under this Warrant and, if applicable, an
amended Warrant representing the remaining number of shares purchasable hereunder, as determined
below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company
will issue Common Stock in accordance with the following formula:

	 	 	 	 	 
	
 
	 	 	 	X = Y(A-B)
	
 
	 	 	 	 
	Where:

	 	X =

Y =
	 	A

the number of shares of Common Stock to be issued to the Warrantholder.

the number of shares of Common Stock requested to be exercised under this Warrant.

	 	 	 	A = the fair market value of one (1) share of Common Stock at the
time of issuance of such shares of Common Stock.

	 	 	 	B = the Exercise Price.

For purposes of the above calculation, current fair market value of Common Stock shall mean
with respect to each share of Common Stock:

(i) if the Common Stock is traded on any registered national stock exchange, the
average of the closing prices of the Common Stock on such exchange over the five trading
days ending on the date of exercise;

(ii) if the Common Stock is traded over-the-counter, but not on a registered national
stock exchange, the average of the closing bid prices over the 30-day period ending on the
date of exercise; and

(iii) if there is no active public market for the Common Stock, the value thereof, as
determined in good faith by the Board of Directors of the Company upon due consideration of
the proposed determination thereof by the Holder.

Upon partial exercise, the Company shall promptly issue a new Warrant representing the
remaining number of shares purchasable hereunder. All other terms and conditions of such Warrant
shall be identical to those contained herein, including, but not limited to the Effective Date
hereof.

(b) Exercise Prior to Expiration. To the extent this Warrant is not previously
exercised as to all Common Stock subject hereto, and if the fair market value of one share of the
Common Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed
automatically exercised, with respect to any portion here that is vested and exercisable pursuant
to Section 3(a) (even if not surrendered), immediately before its expiration. For purposes of such
automatic exercise, the fair market value of one share of the Common Stock upon such expiration
shall be determined pursuant to Section 3(a). To the extent this Warrant or any portion thereof is
deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify
the Warrantholder of the number of shares of Common Stock, if any, the Warrantholder is to receive
by reason of such automatic exercise.

	 	 	SECTION 4. RESERVATION OF SHARES.

During the term of this Warrant, the Company will at all times have authorized and reserved a
sufficient number of shares of its Common Stock to provide for the exercise of the rights to
purchase Common Stock as provided for herein.

	 	 	SECTION 5. NO FRACTIONAL SHARES OR SCRIP.

No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment
therefor upon the basis of the Exercise Price then in effect.

	 	 	SECTION 6. NO RIGHTS AS STOCKHOLDER.

This Warrant does not entitle the Warrantholder to any voting rights or other rights as a
stockholder of the Company prior to the exercise of this Warrant.

	 	 	SECTION 7. WARRANTHOLDER REGISTRY.

The Company shall maintain a registry showing the name and address of the registered holder of
this Warrant. Warrantholder’s initial address, for purposes of such registry, is set forth below
Warrantholder’s signature on this Warrant. Warrantholder may change such address by giving written
notice of such changed address to the Company.

	 	 	SECTION 8. ADJUSTMENT RIGHTS.

The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject
to adjustment, as follows:

(a) Merger Event. If at any time there shall be Merger Event, then, as a part of such
Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled
to receive, upon exercise of this Warrant, the number of shares of Common Stock or other securities
or property of the successor corporation resulting from such Merger Event that would have been
issuable if Warrantholder had exercised this Warrant immediately prior to the Merger Event. In any
such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors)
shall be made in the application of the provisions of this Warrant with respect to the rights and
interests of the Warrantholder after the Merger Event to the end that the provisions of this
Warrant (including adjustments of the Exercise Price and number of shares of Common Stock
purchasable) shall be applicable in their entirety, and to the greatest extent possible. Without
limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the
successor or surviving entity shall assume the obligations of the Company under this Warrant. In
connection with a Merger Event and upon Warrantholder’s written election to the Company, the
Company shall cause this Warrant to be exchanged for the consideration that Warrantholder would
have received if Warrantholder chose to exercise its right to have shares issued pursuant to the
Net Issuance provisions of this Warrant without actually exercising such right, acquiring such
shares and exchanging such shares for such consideration.

(b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company
at any time shall, by combination, reclassification, exchange or subdivision of securities or
otherwise, change any of the securities as to which purchase rights under this Warrant exist into
the same or a different number of securities of any other class or classes (other than a change in
par value or from par value to no par value or no par value to par value or as a result of a stock
dividend or subdivision, split-up or combination of shares), this Warrant shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as
the result of such change with respect to the securities which were subject to the purchase rights
under this Warrant immediately prior to such combination, reclassification, exchange, subdivision
or other change.

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or
subdivide its Common Stock, (i) in the case of a subdivision, the Exercise Price shall be
proportionately decreased, and the number of shares of Common Stock issuable upon exercise of this
Warrant shall be proportionately increased, or (ii) in the case of a combination, the Exercise
Price shall be proportionately increased, and the number of shares of Common Stock issuable upon
the exercise of this Warrant shall be proportionately decreased.

(d) Stock Dividends. If the Company at any time while this Warrant is outstanding and
unexpired shall pay a dividend with respect to the Common Stock payable in Common Stock, then the
Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled
to receive such dividend or distribution, to that price determined by multiplying the Exercise
Price in effect immediately prior to such date of determination by a fraction (A) the numerator of
which shall be the total number of shares of Common Stock outstanding immediately prior to such
dividend or distribution, and (B) the denominator of which shall be the total number of shares of
Common Stock outstanding immediately after such dividend or distribution.

(e) Notice of Certain Events. If: (i) the Company shall declare any dividend or
distribution upon its stock, whether in stock, cash, property or other securities (assuming
Warrantholder consents to a dividend involving cash, property or other securities); (ii) the
Company shall offer for subscription pro rata to the holders of its Common any additional shares of
stock of any class or other rights; (iii) there shall be any Merger Event; (iv) the Company shall
sell, lease, license or otherwise transfer all or substantially all of its assets; or (v) there
shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection
with each such event, the Company shall send to the Warrantholder: (A) at least ten (10) days’
prior written notice of the date on which the books of the Company shall close or a record shall be
taken for such dividend, distribution, subscription rights (specifying the date on which the
holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of
such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger
Event, sale, lease, license or other transfer of all or substantially all assets, dissolution,
liquidation or winding up, at least ten (10) days’ prior written notice of the date when the same
shall take place (and specifying the date on which the holders of Common Stock shall be entitled to
exchange their Common Stock for securities or other property deliverable upon such Merger Event,
dissolution, liquidation or winding up).

Each such written notice shall set forth, in reasonable detail, (i) the event requiring the
notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B)
the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the
Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after
giving effect to such adjustment, and shall be given by first class mail, postage prepaid, or by
reputable overnight courier with all charges prepaid, addressed to the Warrantholder at the address
for Warrantholder set forth in the registry referred to in Section 7.

(f) Timely Notice. Failure to timely provide such notice required by subsection (f)
above shall entitle Warrantholder to retain the benefit of the applicable notice period
notwithstanding anything to the contrary contained in any insufficient notice received by
Warrantholder. For purposes of this subsection (g), and notwithstanding anything to the contrary
in Section 12(g), the notice period shall begin on the date Warrantholder actually receives a
written notice containing all the information required to be provided in such subsection (f).

	 	 	SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

(a) Reservation of Common Stock. The Common Stock issuable upon exercise of the
Warrantholder’s rights has been duly and validly reserved and, when issued in accordance with the
provisions of this Warrant, will be validly issued, fully paid and non-assessable, and will be free
of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the
Common Stock issuable pursuant to this Warrant may be subject to restrictions on transfer under
state and/or federal securities laws. The Company has made available to the Warrantholder true,
correct and complete copies of its Charter and current bylaws. The issuance of certificates for
shares of Common Stock upon exercise of this Warrant shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in
connection with such exercise and the related issuance of shares of Common Stock; provided,
that the Company shall not be required to pay any tax that may be payable in respect of any
transfer and the issuance and delivery of any certificate in a name other than that of the
Warrantholder.

(b) Due Authority. The execution, delivery and issuance by the Company of this
Warrant and the performance of all obligations of the Company hereunder, including the issuance to
Warrantholder of the shares of Common Stock issuable hereunder, have been duly authorized by all
necessary corporate action on the part of the Company. This Warrant constitutes legal, valid and
binding obligation of the Company, enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by bankruptcy, insolvency, reorganization, fraudulent
conveyance, moratorium, or other laws affecting the enforcement of creditors’ rights in general,
and except that the enforceability of this Warrant is subject to general principles of equity.

(c) Consents and Approvals. No consent or approval of, giving of notice to,
registration with, or taking of any other action in respect of any state, federal or other
governmental authority or agency is required with respect to the execution, delivery and
performance by the Company of its obligations under this Warrant, except for the filing of notices
pursuant to Regulation D under the Act, and any filing required by applicable state securities law
and any required filings or notifications regarding the issuance or listing of additional shares
with the Nasdaq Stock Market LLC.

(d) Exempt Transaction. Subject to the accuracy of the Warrantholder’s
representations in Section 10, the issuance of the Common Stock upon exercise of this Warrant will
constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act and
(ii) the qualification requirements of the applicable state securities laws.

(e) Compliance with Rule 144. If the Warrantholder proposes to sell Common Stock
issuable upon the exercise of this Warrant and in compliance with Rule 144 promulgated by the SEC,
then, upon Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten days after receipt of such request, a written statement confirming the
Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such
Rule may be amended from time to time.

	 	 	SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.

This Warrant has been entered into by the Company in reliance upon the following
representations and covenants of the Warrantholder:

(a) Investment Purpose. The right to acquire Common Stock or the Common Stock
issuable upon exercise of the Warrantholder’s rights contained herein will be acquired for
investment and not with a view to the sale or distribution of any part thereof, and the
Warrantholder has no present intention of selling or engaging in any public distribution of the
same except pursuant to a registration statement under the Act or an exemption from the
registration requirements of the Act.

(b) Private Issue. The Warrantholder understands (i) that the Common Stock issuable
upon exercise of this Warrant is not registered under the Act or qualified under applicable state
securities laws on the ground that the issuance contemplated by this Warrant will be exempt from
the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on
such exemption is predicated on the representations set forth in this Section 10.

(c) Financial Risk. The Warrantholder has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of its investment, and has
the ability to bear the economic risks of its investment.

(d) Restrictions on Transfer. The Warrantholder understands that the Warrant and the
Warrant Shares have not been and are not being registered under the Act or any applicable state
securities laws and, consequently, the Warrantholder may have to bear the risk of owning the
Warrants and the Warrant Shares for an indefinite period of time. The Warrantholder also
understands that any sale of (A) the Warrants or (B) the Warrant Shares that might be made by it in
reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions
of that Rule.

(e) Legends. The Warrantholder understands and agrees that all certificates
evidencing the Warrant Shares to be issued to the Warrantholder may bear a legend in substantially
the following form:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE
SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR
TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT SUCH OPINION IS REQUIRED
PURSUANT TO THE WARRANT UNDER WHICH THE SECURITIES WERE ISSUED.

(f) Accredited Investor. Warrantholder is an “accredited investor” within the meaning
of the Securities and Exchange Rule 501 of Regulation D, as presently in effect.

	 	 	SECTION 11. TRANSFERS.

The Warrantholder will not, directly or indirectly, offer, sell, pledge, transfer or otherwise
dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the
Warrant or Warrant Shares except in accordance with the Act. Subject to compliance with applicable
federal and state securities laws, this Warrant and all rights hereunder are transferable, in whole
or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this
Warrant properly endorsed. Notwithstanding the foregoing, neither the Warrant nor the Warrant
Shares may be transferred unless (i) the resale of such securities is registered pursuant to an
effective registration statement under the Act or (ii) the Warrants or Warrant Shares to be sold or
transferred may be sold or transferred pursuant to an exemption from such registration. The
transfer of this Warrant shall be recorded on the books of the Company upon delivery by the
Warrantholder to the Company of a notice of transfer in the form attached hereto as Exhibit III
(the “Transfer Notice”) at its principal offices, and the payment to the Company of all
transfer taxes and other governmental charges imposed on such transfer. Until the Company receives
such Transfer Notice and payment, if required, the Company may treat the registered owner hereof as
the owner for all purposes.

	 	 	SECTION 12. MISCELLANEOUS.

(a) Remedies. In the event of any default hereunder, the non-defaulting party may
proceed to protect and enforce its rights either by suit in equity and/or by action at law,
including but not limited to an action for damages as a result of any such default, and/or an
action for specific performance for any default where Warrantholder will not have an adequate
remedy at law and where damages will not be readily ascertainable. The Company expressly agrees
that it shall not oppose an application by the Warrantholder or any other person entitled to the
benefit of this Warrant requiring specific performance of any or all provisions hereof or enjoining
the Company from continuing to commit any such breach of this Warrant.

(b) No Impairment of Rights. The Company will not, by amendment of its Charter or
through any other means, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate in order to protect the
rights of the Warrantholder against impairment.

(c) Severability. In the event any one or more of the provisions of this Warrant
shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this
Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced
by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision.

(d) Notices. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, or other communication that is required, contemplated, or permitted
under this Warrant or with respect to the subject matter hereof shall be in writing, and shall be
deemed to have been validly given, delivered, and received upon the earlier of: (i) the first
business day after transmission by facsimile or hand delivery or deposit with an overnight express
service or overnight mail delivery service; or (ii) the third calendar day after deposit in the
United States mails, with proper first class postage prepaid, and shall be addressed to the party
to be notified as set forth on the signature page to this Warrant or to such other address as each
party may designate for itself by like notice.

(e) Entire Agreement; Amendments. This Warrant constitutes the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof, and supersedes and
replaces in its entirety any prior proposals, term sheets, letters, negotiations or other documents
or agreements, whether written or oral, with respect to the subject matter hereof. None of the
terms of this Warrant may be amended except by an instrument executed by each of the parties
hereto.

(f) Headings. The various headings in this Warrant are inserted for convenience only
and shall not affect the meaning or interpretation of this Warrant or any provisions hereof.

(g) Advice of Counsel. Each of the parties represents to each other party hereto that
it has discussed (or had an opportunity to discuss) with its counsel this Warrant and,
specifically, the provisions of Sections 12(j), 12(k) and 12(l).

(h) No Strict Construction. The parties hereto have participated jointly in the
negotiation and drafting of this Warrant. In the event an ambiguity or question of intent or
interpretation arises, this Warrant shall be construed as if drafted jointly by the parties hereto
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of
the authorship of any provisions of this Warrant.

(i) No Waiver. No omission or delay by any party to this Warrant at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms,
covenants or provisions hereof by such other party, shall be a waiver of any such right or remedy
to which such party is entitled, nor shall it in any way affect the right of such party to enforce
such provisions thereafter.

(j) Survival. All agreements, representations and warranties contained in this
Warrant shall be for the benefit of the Warrantholder and shall survive the execution and delivery
of this Warrant.

(k) Governing Law. This Warrant shall be governed by, and construed and enforced in
accordance with, the laws of the State of New York, excluding conflict of laws principles that
would cause the application of laws of any other jurisdiction.

(l) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under
or related to this Warrant may be brought in any state or federal court of competent jurisdiction
located in Santa Clara County, California. By execution and delivery of this Warrant, each party
hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County,
California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, California;
(c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid
courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with
this Warrant.

(m) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert
person and the parties wish applicable state and federal laws to apply, the parties desire that
their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND
WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION,
CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”)
ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE
AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons
other than Borrower and Lender; Claims that arise out of or are in any way connected to the
relationship between the Company and Warrantholder; and any Claims for damages, breach of contract,
specific performance, or any equitable or legal relief of any kind, arising out of this Warrant.

(n) Counterparts. This Warrant and any amendments, waivers, consents or supplements
hereto may be executed in any number of counterparts, and by different parties hereto in separate
counterparts, each of which when so delivered shall be deemed an original, but all of which
counterparts shall constitute but one and the same instrument.

[Remainder of Page Intentionally Left Blank]

1

IN WITNESS WHEREOF, the parties hereto have caused this Warrant to be executed by its
officers thereunto duly authorized as of the Effective Date.

	 	 	 	 	 
	COMPANY:
	 	MEMORY PHARMACEUTICALS CORP.

	 
	 	By:  /s/ James R. Sulat

	 
	 	Print Name: James R. Sulat

	 
	 	Title:   President and Chief Executive Officer

	Notice Address:
	 	Memory Pharmaceuticals Corp.

	 
	 	Attn:  Mike Smith

	 
	 	100 Philips Parkway
	 
	 	Montvale, New Jersey 07645

	 
	 	Facsimile: (201) 802-7190

	 
	 	with a copy to:

	 
	 	Memory Pharmaceuticals Corp.

	 
	 	Attn:  Jzaneen Lalani, Esq.

	 
	 	100 Philips Parkway
	 
	 	Montvale, New Jersey 07645

	 
	 	Facsimile: (201) 802-7190

	WARRANTHOLDER:
	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

	 
	 	By:  /s/ Scott Harvey

	 
	 	Name: Scott Harvey

	 
	 	Title: Chief Legal Officer

	Notice Address:
	 	Hercules Technology Growth Capital, Inc..

	 
	 	Attn: Manuel Henriquez and Parag Shah

	 
	 	400 Hamilton Avenue, Suite 310
	 
	 	Palo Alto, CA 94301

	 
	 	Facsimile:  650-473-9194

2

EXHIBIT I

NOTICE OF EXERCISE

To: [     ]

	(1)	 	The undersigned Warrantholder hereby elects to purchase [     ] shares of the Common Stock
of MEMORY PHARMACEUTICALS CORP., pursuant to the terms of the Warrant dated the 16th day of
March, 2007 (the “Warrant”) between Memory Pharmaceuticals Corp. and the Warrantholder, and
[if CASH PAYMENT, insert: tenders herewith payment of the Purchase Price in full, together
with all applicable transfer taxes, if any.] [if NET ISSUANCE, insert: elects pursuant to
Section 3(a) of the Warrant to effect a Net Issuance.]

	(2)	 	Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below.

(Name)

(Address)

	(3)	 	The undersigned represents that (i) the aforesaid shares of Common Stock are being acquired
for the account of the undersigned for investment and not with a view to, or for resale in
connection with, the distribution thereof and that the undersigned has no present intention of
distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business
affairs and financial condition and has acquired sufficient information about the Company to
reach an informed and knowledgeable decision regarding its investment in the Company; (iii)
the undersigned is experienced in making investments of this type and has such knowledge and
background in financial and business matters that the undersigned is capable of evaluating the
merits and risks of this investment and protecting the undersigned’s own interests; (iv) the
undersigned is aware that the aforesaid shares of Common Stock may not be sold pursuant to
Rule 144 adopted under the Securities Act unless certain conditions are met and until the
undersigned has held the shares for the number of years prescribed by Rule 144; and (v) the
undersigned agrees not to make any disposition of all or any part of the aforesaid shares of
Common Stock unless and until there is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made in accordance
with said registration statement, or such registration is not required.

	 	 	 
	WARRANTHOLDER:

	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

By:
	
 
	 	 
	
 
	 	Name: Scott Harvey

Title: Chief Legal Officer

Date:
	
 
	 	 

3

EXHIBIT II

ACKNOWLEDGMENT OF EXERCISE

The undersigned [     ], hereby acknowledge receipt of the “Notice
of Exercise” from Hercules Technology Growth Capital, Inc., to purchase [     ] shares of the
Common Stock of Memory Pharmaceuticals Corp., pursuant to the terms of the Warrant, and further
acknowledges that [     ] shares remain subject to purchase under the terms of the Warrant.

	 	 	 
	COMPANY:

	 	MEMORY PHARMACEUTICALS CORP.
	 
	 	 
	
 
	 	By:
	
 
	 	 
	
 
	 	Title:
	
 
	 	 
	
 
	 	Date:
	
 
	 	 

4

EXHIBIT III

TRANSFER NOTICE

(To transfer or assign the foregoing Warrant execute this form and supply required information. Do
not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby transferred
and assigned to

      (the “Transferee”)

(Please Print)

whose address is

Dated:

Holder’s Signature:

Holder’s Address:

Signature Guaranteed:

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.

The Transferee hereby acknowledges and agrees that it is subject to the terms and conditions of the
Warrant to the same extent as if the Transferee were the original Warrantholder thereunder. The
Transferee hereby represents and Warrants to the Company that each of the representations and
warranties set forth in Section 10 of the Warrant are true and correct in all respects as if made
by the Transferee on the date hereof.

Name of Transferee:      

Signature:      

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]